MIDA


Public lists: Pharma Startups (4743)

MIDA, LLC is a research and development drug therapeutic company focused on infectious disease indications.

MIDA, LLC is a research and development drug therapeutic company focused on infectious disease indications.

Company (Alive / Active)

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
MIDA $0M Apr 19, 2019
See all 15 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related MIDA Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Inimex Pharmaceuticals

Vancouver, British Columbia, Canada
Alive / ActiveInimex Pharmaceuticals, Inc. is focused on the development and commercialization of Innate Defense Regulators (IDRs), first in class drugs that selectively trigger the body's innate defenses without causing inflammation. IDR products have major market potential for infectious disease, cancer, and inflammatory disease. These products will reduce morbidity and mortality in the rapidly growing population of immune suppressed and elderly patients who are "at-risk" for these disorders. IDR produc...Show allLogin to see details

Immune Design

Seattle, Washington, United States
AcquiredImmune Design is a clinical-stage biotechnology company developing two synergistic platforms of vaccines designed to treat cancer, infectious diseases, allergy, and autoimmune disorders. The company employs technologies that target dendritic cells for more precise activation of the immune response. These include DCVex, a lentiviral vector platform engineered to deliver antigen-encoding nucleic acids directly to dendritic cells in vivo, and GLAAS, a TLR4 agonist platform that activates dendritic ...Show allLogin to see details
See all 15 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)